Waldenström's macroglobulinemia medical therapy

Waldenström's macroglobulinemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Waldenström's macroglobulinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Bone Marrow Aspiration and Biopsy
Electrophoresis and Immunofixation
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Waldenström's macroglobulinemia medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Waldenström's macroglobulinemia medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Waldenström's macroglobulinemia medical therapy
CDC on Waldenström's macroglobulinemia medical therapy
Waldenström's macroglobulinemia medical therapy in the news
Blogs on Waldenström's macroglobulinemia medical therapy
Directions to Hospitals Treating Waldenström's macroglobulinemia
Risk calculators and risk factors for Waldenström's macroglobulinemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Overview

Risk stratification determines the protocol of management used for Waldenström's macroglobulinemia patients.

Medical Therapy

There are several different options for Waldenström Macroglobulinemia.

Asymptomatic/Smoldering Waldenström's macroglobulinemia

Patients who do not have symptoms and whose cancer does not seem to be progressing often do not need treatment. They can be monitored every 3-6 months - a 'wait and watch approach'.

Symptomatic Waldenström's macroglobulinemia

Symptomatic patients with Waldenström Macroglobulinemia are started on chemotherapy depending on the stage.

Initial stage of Waldenström's macroglobulinemia associated with

• Neuropathy,
• Anemia or cytopenias,
• Low-volume nodal involvement, and
• Asymptomatic splenomegaly

Treatment: Single-agent Rituximab therapy

Late stage of Waldenström's macroglobulinemia associated with

• Adenopathy,
• Symptomatic splenomegaly,
• Cytopenias,
• Hyperviscosity syndrome,
• Neuropathy, or
• Constitutional symptoms

Treatment regimen used:

CHOP-R regimen:

• Cyclophosphamide 750 mg/m2 IV day 1;
• Doxorubicin 50 mg/m2;
• Vincristine 1.4 mg/m2 IV (max 2 mg) day 1;
• Prednisone 50 mg/m2 PO days 1-5;
• Rituximab 375 mg/m2 IV day 1;
• Primary: Repeat 21 day cycle for 6-8 cycles

• Adverse Effect:

• Nausea
• Alopecia
• Granulocytopenia

Ibrutinib 420 mg PO once daily until disease progression

• Adverse Effect:

• Fatigue
• Cytopenia

Rituximab 375 mg/m2 IV once weekly x 4 weeks

• Adverse Effect:

• Infusion related reaction
• Infections

Fludarabine/Rituximab regimen:

• Fludarabine 25 mg/m2 IV days 1-5;
• Rituximab 375 mg/m2 IV day 1;
• Repeat 28 day cycle for 4-6 cycles

• Adverse Effect:

• Neutropenia (63%)
• Thrombocytopenia
• Pneumonia

FCR regimen:

• Fludarabine 25 mg/m2 IV days 1-3
• Cyclophosphamide 250 mg/m2 IV days 1-3
• Rituximab 375 mg/m2 IV day 1
• Primary: Repeat 28 day cycle for 4-6 cycles
• May also be given with mitoxantrone 10 mg/m2 on day 1

• Adverse Effect:

• Neurtropenia

BR regimen:

• Bendamustine 90 mg/m2 IV days 1-2
• Rituximab 375 mg/m2 IV day 1
• Primary: Repeat 21 day cycle for 6 cycles

• Adverse Effect:

• Myelosupression
• Neutropenia
• Thrombocytopenia

BDR regimen:

• Bortezomib 1.3 mg/m2plus
• Dexamethasone 40 mg IV days 1, 4, 8, and 11
• Rituximab 375 mg/m2 IV day 11
• Primary: Repeat 21 day cycle for 4 cycles

• Adverse Effect:

• Peripheral neuropathy - reversible in 61% of patients

DRC regimen:

• Dexamethasone 20 mg IV day 1
• Rituximab 375 mg/m2 IV day 1
• Cyclophosphamide 100 mg/m2 PO BID days 1-5
• Primary: Repeat 21 day cycle for 6 cycles

• Adverse Effect:

• Neutropenia
• Rituximab associated toxicity

CR regimen:

• Cladribine 0.1 mg/kg SC days 1-5
• Rituximab 375 mg/m2 IV day 1
• Primary: Repeat 28 day cycle for 4 cycles

• Adverse Effect:

• Anemia
• Neurological symptoms
• symptomatic cryoglobulinemia
• Thrombocytopenia

Hyperviscosity syndrome

• Plasmapheresis is recommended emergent treatment option for patients with Waldenström Macroglobulinemia who develop hyperviscosity symptoms.
• Plasmapheresis temporarily lowers IgM levels by removing some of the abnormal IgM from the blood, which makes the blood thinner.
• However, plasmapheresis does not affect the lymphoma cells.
• Plasmapheresis is usually given until chemotherapy starts to work.
• Plasmapheresis is combined with chemotherapy to control the disease for a longer period of time.

Salvage approach

• Stem cell transplant is used in patients whose lymphoma relapses or is not responding to other treatments (refractory).